Adaptimmune Therapeutics

-$0.07 (-4.27%) As of 12:05 PM UTC pre-market

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ADAP and other ETFs, options, and stocks.

About ADAP

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.

CEO
Adrian Rawcliffe
Employees
494
Headquarters
Abingdon, Oxfordshire
Founded
2014

ADAP Key Statistics

Market cap
257.17M
Price-Earnings ratio
—
Dividend yield
—
Average volume
473.66K
High today
$1.76
Low today
$1.55
Open price
$1.73
Volume
263.37K
52 Week high
$6.86
52 Week low
$1.26

ADAP Earnings

-$0.30
-$0.15
-$0.01
$0.14
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Estimated
-$0.22 per share
Actual
-$0.05 per share
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure